Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
Scientific Reports
|
February 16, 2023
Impact of the SARS-CoV-2 pandemic on the survival of patients with high-grade glioma and best practice recommendations
Marco M E Vogel, Arthur Wagner, Jens Gempt, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 18, 2020
Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [<sup>68</sup>Ga]PSMA-PET-guided metastasis-directed therapy
Marco M E Vogel, Stephanie G C Kroeze, Christoph Henkenberens, et al.
European Urology Focus
|
September 10, 2019
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation
Stephanie G C Kroeze, Christoph Henkenberens, Nina Sophie Schmidt-Hegemann, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
February 1, 2020
Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy-a multicenter retrospective study
N-S Schmidt-Hegemann, S G C Kroeze, C Henkenberens, et al.
Frontiers in Oncology
|
May 27, 2021
Combining <sup>68</sup>Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study
Simon Kirste, Stephanie G C Kroeze, Christoph Henkenberens, et al.
BMC Cancer
|
May 1, 2020
Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy
Ann-Kathrin Oehus, Stephanie G C Kroeze, Nina-Sophie Schmidt-Hegemann, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 8, 2024
European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy
Sophia Scharl, Constantinos Zamboglou, Iosif Strouthos, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 12, 2026
PSA persistence in the PSMA PET era: reassessing a risk factor after radical prostatectomy
Sophia Scharl, Reinhard Thamm, Constantinos Zamboglou, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 22, 2023
The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy
Sonja Adebahr, Alexander Althaus, Sophia Scharl, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 19, 2022
The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis
Simon K B Spohn, Andrea Farolfi, Sarah Schandeler, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
Scientific Reports
|
February 16, 2023
Impact of the SARS-CoV-2 pandemic on the survival of patients with high-grade glioma and best practice recommendations
Marco M E Vogel, Arthur Wagner, Jens Gempt, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 18, 2020
Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [<sup>68</sup>Ga]PSMA-PET-guided metastasis-directed therapy
Marco M E Vogel, Stephanie G C Kroeze, Christoph Henkenberens, et al.
European Urology Focus
|
September 10, 2019
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation
Stephanie G C Kroeze, Christoph Henkenberens, Nina Sophie Schmidt-Hegemann, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
February 1, 2020
Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy-a multicenter retrospective study
N-S Schmidt-Hegemann, S G C Kroeze, C Henkenberens, et al.
Frontiers in Oncology
|
May 27, 2021
Combining <sup>68</sup>Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study
Simon Kirste, Stephanie G C Kroeze, Christoph Henkenberens, et al.
BMC Cancer
|
May 1, 2020
Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy
Ann-Kathrin Oehus, Stephanie G C Kroeze, Nina-Sophie Schmidt-Hegemann, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 8, 2024
European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy
Sophia Scharl, Constantinos Zamboglou, Iosif Strouthos, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 12, 2026
PSA persistence in the PSMA PET era: reassessing a risk factor after radical prostatectomy
Sophia Scharl, Reinhard Thamm, Constantinos Zamboglou, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 22, 2023
The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy
Sonja Adebahr, Alexander Althaus, Sophia Scharl, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 19, 2022
The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis
Simon K B Spohn, Andrea Farolfi, Sarah Schandeler, et al.
Page
of 5